Subtopic Deep Dive

EMMPRIN/CD147 in Inflammatory Signaling
Research Guide

What is EMMPRIN/CD147 in Inflammatory Signaling?

EMMPRIN/CD147 is a transmembrane glycoprotein that induces matrix metalloproteinases (MMPs) and cytokines through interactions with cyclophilin A and NFAT pathways, driving inflammatory signaling in diseases.

CD147, also known as basigin or EMMPRIN, functions as an extracellular matrix metalloproteinase inducer, promoting leukocyte migration and tissue remodeling in inflammation (Muramatsu and Miyauchi, 2003; 277 citations). It interacts with cyclophilin A to activate inflammatory responses, as detailed in studies on human diseases (Nigro et al., 2013; 461 citations). Over 10 key papers from 2001-2020, with 568 citations for the top-cited work on CD147 distribution in COVID-19 risk factors (Radzikowska et al., 2020).

Curated Papers

Key Challenges

Why It Matters

CD147 induces MMP secretion in tumors and chronic inflammation, linking extracellular matrix signaling to immune dysregulation in heart failure and hepatitis C cirrhosis (Zucker et al., 2001; 260 citations; Shackel et al., 2002; 164 citations). In inflammatory diseases, cyclophilin A-CD147 interactions drive cytokine release and leukocyte activation, offering therapeutic targets (Yurchenko et al., 2010; 242 citations). Xiong et al. (2014; 220 citations) highlight its role in cancer progression via MMP and cytokine stimulation, impacting treatments for asthma, COPD, and COVID-19 comorbidities (Radzikowska et al., 2020).

Key Research Challenges

Dissecting CD147-CyPA Interactions

Defining precise molecular mechanisms of cyclophilin A binding to CD147 remains challenging due to conflicting roles in inflammation versus immune regulation. Yurchenko et al. (2005; 180 citations) and Yurchenko et al. (2010; 242 citations) identify CyPA-CD147 as anti-inflammatory targets but note variability in disease contexts. Structural studies are needed for inhibitor design.

Quantifying MMP Induction Pathways

Linking CD147 to specific MMPs and NFAT activation in leukocytes is complicated by tissue-specific expression. Deschamps and Spinale (2006; 189 citations) map MMP pathways in heart failure, while Somerville et al. (2003; 295 citations) review MMP regulation tricks. Pathway specificity requires advanced proteomics.

Therapeutic Targeting in Comorbidities

Developing CD147 inhibitors for inflammation in COVID-19, obesity, and hypertension faces off-target effects on reproduction and neural function. Radzikowska et al. (2020; 568 citations) map CD147 in disease tissues, and Nigro et al. (2013; 461 citations) detail CyPA's broad disease roles. Clinical translation needs disease-specific validation.

Essential Papers

Distribution of ACE2, CD147, CD26, and other SARS‐CoV‐2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID‐19 risk factors

Urszula Radzikowska, Mei Ding, Ge Tan et al. · 2020 · Allergy · 568 citations

Abstract Background Morbidity and mortality from COVID‐19 caused by novel coronavirus SARS‐CoV‐2 is accelerating worldwide, and novel clinical presentations of COVID‐19 are often reported. The rang...

Cyclophilin A: a key player for human disease

Patrizia Nigro, Giulio Pompilio, M. C. Capogrossi · 2013 · Cell Death and Disease · 461 citations

Abstract Cyclophilin A (CyPA) is a ubiquitously distributed protein belonging to the immunophilin family. CyPA has peptidyl prolyl cis - trans isomerase (PPIase) activity, which regulates protein f...

Matrix metalloproteinases: old dogs with new tricks.

Robert Somerville, Samantha A. Oblander, Suneel Apte · 2003 · Genome Biology · 295 citations

Basigin (CD147): a multifunctional transmembrane protein involved in reproduction, neural function, inflammation and tumor invasion.

Takashi Muramatsu, T. Miyauchi · 2003 · PubMed · 277 citations

Basigin (Bsg) is a transmembrane glycoprotein with two immunoglobulin-like domains, and forms a family with embigin and neuroplastin. In these proteins a conserved glutamic acid is present in the m...

Tumorigenic Potential of Extracellular Matrix Metalloproteinase Inducer

Stanley Zucker, Michelle Hymowitz, Ellen E. Rollo et al. · 2001 · American Journal Of Pathology · 260 citations

Cyclophilin–CD147 interactions: a new target for anti-inflammatory therapeutics

Vyacheslav Yurchenko, Stephanie L. Constant, Elan Eisenmesser et al. · 2010 · Clinical & Experimental Immunology · 242 citations

Summary CD147 is a widely expressed plasma membrane protein that has been implicated in a variety of physiological and pathological activities. It is best known for its ability to function as extra...

The Biological Function and Clinical Utilization of CD147 in Human Diseases: A Review of the Current Scientific Literature

Lijuan Xiong, Carl K. Edwards, Lijun Zhou · 2014 · International Journal of Molecular Sciences · 220 citations

CD147 or EMMPRIN is a member of the immunoglobulin superfamily in humans. It is widely expressed in human tumors and plays a central role in the progression of many cancers by stimulating the secre...

Reading Guide

Foundational Papers

Start with Nigro et al. (2013; 461 citations) for CyPA overview, Muramatsu and Miyauchi (2003; 277 citations) for CD147 functions in inflammation, and Yurchenko et al. (2010; 242 citations) for therapeutic interactions.

Recent Advances

Study Radzikowska et al. (2020; 568 citations) for CD147 in COVID-19 and comorbidities, Xiong et al. (2014; 220 citations) for clinical utilization in diseases.

Core Methods

Core techniques: PPIase activity assays for CyPA (Nigro et al., 2013), MMP zymography (Somerville et al., 2003), co-IP for protein interactions (Yurchenko et al., 2005), and IHC for tissue distribution (Radzikowska et al., 2020).

How PapersFlow Helps You Research EMMPRIN/CD147 in Inflammatory Signaling

Discover & Search

Research Agent uses searchPapers and exaSearch to find CD147-MMP papers like 'Cyclophilin–CD147 interactions' (Yurchenko et al., 2010), then citationGraph reveals clusters around Nigro et al. (2013; CyPA review) and findSimilarPapers uncovers related CyPA-CD147 therapeutics.

Analyze & Verify

Analysis Agent applies readPaperContent to extract MMP induction data from Muramatsu and Miyauchi (2003), verifies claims with CoVe chain-of-verification, and runs PythonAnalysis for statistical correlation of CD147 expression with inflammation markers across Radzikowska et al. (2020) datasets, graded by GRADE for evidence strength.

Synthesize & Write

Synthesis Agent detects gaps in CD147-NFAT pathway integration across papers, flags contradictions in CyPA roles (Yurchenko et al., 2005 vs. 2010), while Writing Agent uses latexEditText, latexSyncCitations for Nigro et al. (2013), and latexCompile to generate review manuscripts with exportMermaid diagrams of signaling cascades.

Use Cases

"Correlate CD147 expression levels with MMP secretion in COPD patient data from recent papers."

Research Agent → searchPapers('CD147 MMP COPD') → Analysis Agent → runPythonAnalysis(pandas correlation on Radzikowska et al. 2020 data) → matplotlib plots of expression-MMP trends.

"Draft LaTeX figure of CD147-CyPA inflammatory pathway with citations."

Synthesis Agent → gap detection on Yurchenko et al. 2010 → Writing Agent → latexGenerateFigure + latexSyncCitations(Nigro 2013) → latexCompile → PDF with pathway diagram.

"Find GitHub repos analyzing CD147 sequencing data from inflammation studies."

Research Agent → searchPapers('CD147 inflammation RNA-seq') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → curated code for NFAT pathway simulation.

Automated Workflows

Deep Research workflow conducts systematic review of 50+ CD147 papers via searchPapers → citationGraph → structured report on MMP induction across diseases (Radzikowska 2020 cluster). DeepScan applies 7-step analysis with CoVe checkpoints to verify CyPA-CD147 interactions in Yurchenko et al. (2010), outputting graded evidence summaries. Theorizer generates hypotheses on CD147 inhibitors from Nigro et al. (2013) and Muramatsu (2003) literature synthesis.

Try Doxa for EMMPRIN/CD147 in Inflammatory Signaling Research

Frequently Asked Questions

What is the definition of EMMPRIN/CD147 in inflammatory signaling?

EMMPRIN/CD147 is a transmembrane protein that induces MMPs and cytokines via cyclophilin A interactions and NFAT pathways, promoting inflammation (Muramatsu and Miyauchi, 2003).

What are key methods for studying CD147 signaling?

Methods include co-immunoprecipitation for CyPA-CD147 binding (Yurchenko et al., 2005), tissue expression mapping via immunohistochemistry (Radzikowska et al., 2020), and MMP activity assays (Zucker et al., 2001).

What are the most cited papers on this topic?

Top papers are Radzikowska et al. (2020; 568 citations) on CD147 in COVID-19 tissues, Nigro et al. (2013; 461 citations) on CyPA diseases, and Yurchenko et al. (2010; 242 citations) on anti-inflammatory targets.

What are open problems in CD147 inflammatory research?

Challenges include tissue-specific inhibitor design, resolving CyPA pro- vs. anti-inflammatory roles (Nigro et al., 2013), and validating pathways in human comorbidities (Deschamps and Spinale, 2006).